Biotech Financing Roundup: Where the Money's At

There's a perceived transatlantic divide when it comes to biotechnology financing. European firms, the conventional wisdom goes, lack the VC support of their North American counterparts and thus are at an inherent disadvantage: they can't afford to invest in as many projects, drug candidates, or clinical trials. Therefore, fewer European firms achieve critical mass, go public, develop great drugs, and make their founders, investors and executives wildly wealthy.

There's a modicum of truth to this—certainly North American biotechs have outpaced their European cousins over the years in terms of valuation growth and development success. (See "UK Biotech Learns...